We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$76.4M
Cap. Flow %
4.35%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.28%
2 Consumer Discretionary 0.06%
3 Industrials 0.03%
4 Technology 0.03%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$18.2B
$146M 8.3%
3,366,530
+50,007
+2% +$2.14M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$142M 8.1%
3,858,978
+730,000
+23% +$18.4M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$123M 7.03%
17,296,672
– –
ARAV
4
DELISTED
Aravive, Inc. Common Stock
ARAV
$94.1M 5.36%
734,553
+42,272
+6% +$4.46M
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$63.9M 3.64%
2,139,274
+820,000
+62% +$20.9M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$38.1B
$56.6M 3.22%
1,103,475
+985,000
+831% +$45.5M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.65B
$52.4M 2.99%
1,771,029
-998,800
-36% -$30.9M
TVTX icon
8
Travere Therapeutics
TVTX
$5.13B
$51.8M 2.95%
2,807,525
+120,113
+4% +$2.35M
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$48.8M 2.78%
1,818,189
-109,800
-6% -$3.03M
XNCR icon
10
Xencor
XNCR
$1.44B
$38.4M 2.19%
1,607,018
-178,000
-10% -$4.29M
ACRS icon
11
Aclaris Therapeutics
ACRS
$708M
$37.6M 2.14%
1,260,847
– –
TSRO
12
DELISTED
TESARO, Inc.
TSRO
$37.1M 2.11%
241,028
-446,965
-65% -$72.8M
VBIV
13
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$36M 2.05%
218,861
– –
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
$35.2M 2.01%
910,872
+647,000
+245% +$27.1M
AVXS
15
DELISTED
AveXis, Inc. Common Stock
AVXS
$34.1M 1.94%
448,501
-25,030
-5% -$1.55M
EVH icon
16
Evolent Health
EVH
$389M
$32.2M 1.83%
1,444,500
+1,136,700
+369% +$21.8M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$124B
$32.1M 1.83%
293,509
+208,000
+243% +$18.3M
RGNX icon
18
Regenxbio
RGNX
$611M
$26.9M 1.54%
1,396,244
+113,958
+9% +$2.2M
IOVA icon
19
Iovance Biotherapeutics
IOVA
$2.02B
$26.6M 1.51%
3,567,553
– –
CTMX icon
20
CytomX Therapeutics
CTMX
$690M
$26.4M 1.51%
1,530,659
+606,896
+66% +$7.99M
ANAB icon
21
AnaptysBio
ANAB
$1.52B
$24.5M 1.39%
+881,957
New +$20.5M
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
$23.9M 1.36%
2,203,302
+1,450,303
+193% +$14.7M
ARDX icon
23
Ardelyx
ARDX
$1.24B
$23.9M 1.36%
1,886,196
+50,000
+3% +$658K
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$23.4M 1.33%
271,405
-33,126
-11% -$2.39M
DBVT
25
DBV Technologies
DBVT
$801M
$20.8M 1.19%
59,177
-1,887
-3% -$662K
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $76.4M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.